Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSB462 plus lutetium (177Lu) vipivotide tetraxetan in PSMA-positive metastatic castration-resistant prostate cancer
2024-520155-24-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing JSB462 + Pluvicto with Pluvicto control (2 arms). Primary endpoints: PSA50 rate, Safety and 1 more. Planned start Oct 2025; status: authorised.
02
Drugs
luxdegalutamidelutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-520155-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520155-24-00.